Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Brand-Generic Wars Heat Up

Oct 1, 2013

Tension mounts over biosimilars, co-pay coupons, trade, and testing.

Biopharma Innovation in Trouble?

Sep 1, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

Costs and Coverage Challenge Medicare Drug Plans

Aug 1, 2013

Rate cuts and fraud concerns create problems for Part D plans and Part B providers.

Seeking Supply Chain Security

Jul 1, 2013

FDA wants pharma leaders to do more to ensure drug quality at home and abroad. Our Washington correspondent Jill Wechsler reports.

Washington Report: Innovation, Coverage, and Costs

Jun 1, 2013

The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.

Manufacturers Under Pressure to Manage Painkillers

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
May 6, 2013

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

Generic Drug Gains and Grumbles

May 1, 2013

Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.

Full Disclosure for Pharma

Apr 1, 2013

There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.

Another Round of FDA Legislation?

Mar 1, 2013

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

ADVERTISEMENT

Click here